Bernal-Mizrachi, L., Birhiray, R., Bhuriwala, M., Rifkin, R., Lyons, R., Yasenchak, C., Noga, S., Ferreira, I., Cherepanov, D., Savell, A., Xie, Y., Girnius, S. (2025). Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income. Blood. https://doi.org/10.1182/blood-2025-4004